Trump administration officials are having a meeting today to bat around some ideas for executive actions they can take on drug prices, as Jonathan Swan reported last night. And one idea has emerged that will make health care nerds very happy, Bloomberg reports: The White House might promote value-based pricing, in which insurers pay for drugs based on how well they work on specific diseases and patients.
Why it matters: That's actually an idea that wouldn't get a big fight from the pharmaceutical industry. The Pharmaceutical Research and Manufacturers of America has been pushing for legislative and regulatory changes to make it easier to promote those kinds of arrangements. But without legislative changes, the Trump administration may have to settle for using them only in federal programs, like Medicare Part D.